The new KATALYST-AV trial, sponsored by Kardigan, Inc aims to evaluate whether the investigational medication ataciguat can slow the buildup of calcium in the aortic valve in adults with moderate calcific aortic valve stenosis (CAVS).
Thursday, January 8, 2026
Sarasota Memorial’s Kolschowsky Research and Education Institute is now enrolling patients in the international KATALYST-AV trial, which is testing the first potential therapy to treat calcium build up in the aortic valve, rather than just managing symptoms. The study is being led locally by interventional cardiologist Ricardo Yayura, MD. Calcific Aortic Valve Disease (CAVD) is increasing worldwide, with severe cases requiring valve replacement for survival.
Thursday, January 8, 2026